Institution of Chemical Engineers Discusses Process Safety - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Institution of Chemical Engineers Discusses Process Safety


The Institution of Chemical Engineers (IChemE) commented on a study, which found that one in five accidents caused by equipment failures in the chemical process industries are the result of human and organizational errors, and discussed the importance of process safety in a recent press release.

“Accidents caused by equipment failures have many potential causes including contamination, corrosion, poor installation, and mechanical failures. But it is worrying to see that human and organizational failures head the list of contributing factors,” said David Brown, chief executive of IChemE, in the press release. “Competence in process safety lies at the heart of the chemical engineering skill set. Hopefully, our work over the next few years to introduce a new international qualification for process safety professionals, the development of a virtual safety center, and our ambition to promote higher standards in the corporate governance of process safety will help drive down avoidable accidents,” added Brown.

IChemE is a global professional membership organization with offices in Australia, China, Malaysia, New Zealand, Singapore and the UK. Earlier this year, IChemE published a revised technical strategy document,Chemical Engineering Matters, which outlines IChemE’s broader thinking on the areas where the profession creates, maintains, or improves quality of life. One focus of the strategy is the role of chemical engineering in process safety. 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here